<?xml version="1.0" encoding="UTF-8"?>
<p>The lack of evidence of a decline in prevalence over time with an increasing prevalence in Pakistan indicates that the recent introduction of DAA treatment has not yet demonstrated an impact on liver disease burden in the region. Evidence attributes the rapid growth of the epidemic in Pakistan to lower quality health care practices, such as insufficient blood screening, unnecessary therapeutic injections, and reuse of medical needles and syringes.
 <xref rid="hep41491-bib-0010" ref-type="ref">10</xref>, 
 <xref rid="hep41491-bib-0011" ref-type="ref">11</xref>, 
 <xref rid="hep41491-bib-0045" ref-type="ref">45</xref> Progress in DAA rollout in Pakistan is markedly slow, with most patients being treated in the private sector.
 <xref rid="hep41491-bib-0046" ref-type="ref">46</xref> Despite having the second largest epidemic in the world,
 <xref rid="hep41491-bib-0010" ref-type="ref">10</xref>, 
 <xref rid="hep41491-bib-0011" ref-type="ref">11</xref>, 
 <xref rid="hep41491-bib-0028" ref-type="ref">28</xref>, 
 <xref rid="hep41491-bib-0029" ref-type="ref">29</xref> an estimated cumulative total of only 311,000 people have been treated since 2013.
 <xref rid="hep41491-bib-0028" ref-type="ref">28</xref>
</p>
